Patel, M. R., Carneiro, B. A., Delord, J., Bono, J. S. D., Ostheimer, C., Ito, K., Takahashi, Y., Shu, D., Khan, N., Fojo, A. T., Fizazi, K. O. (2026). A phase 1, first-in-human study of DS9051, a novel targeted protein degradation molecule, in patients with advanced/metastatic adrenocortical carcinoma (ACC) or metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.tps3179